News

/News

Poseida Therapeutics Presents Stem Cell Memory CAR-T Therapy for Prostate Cancer at 2018 Keystone Symposia on Emerging Cellular Therapies

SAN DIEGO, February 14, 2018 – Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene engineering technologies into lifesaving cell therapies, presented preclinical data on P-PSMA-101 at the 2018 Keystone Symposia on Emerging Cellular Therapies: T Cells and Beyond. P-PSMA-101 is the company’s PSMA-specific stem cell memory CAR-T drug candidate for the treatment […]

By |February 14th, 2018|News|Comments Off on Poseida Therapeutics Presents Stem Cell Memory CAR-T Therapy for Prostate Cancer at 2018 Keystone Symposia on Emerging Cellular Therapies

Poseida Therapeutics Appoints Martin Giedlin, Ph.D., as Vice President, Technical Operations

SAN DIEGO, Feb. 5, 2018 — Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene engineering technologies into lifesaving cell therapies, today announced that Martin Giedlin, Ph.D., has joined the company as vice president, technical operations.

Dr. Giedlin brings significant expertise in cell therapy process development, manufacturing, and strategy in immunotherapies. Most recently, he […]

By |February 5th, 2018|News|Comments Off on Poseida Therapeutics Appoints Martin Giedlin, Ph.D., as Vice President, Technical Operations

Poseida Therapeutics Announces First Patient Treated in Phase 1 Study of P-BCMA-101 CAR-T Stem Cell Memory Therapy in Patients with Multiple Myeloma

SAN DIEGO, Dec. 18, 2017 — Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene engineering technologies into lifesaving cell therapies, today announced that the first patient has been treated in a Phase 1 study of P-BCMA-101, the company’s lead investigational chimeric antigen receptor T cell (CAR-T) immunotherapy for the treatment of multiple […]

By |December 18th, 2017|News|Comments Off on Poseida Therapeutics Announces First Patient Treated in Phase 1 Study of P-BCMA-101 CAR-T Stem Cell Memory Therapy in Patients with Multiple Myeloma

Multiple Programs Featuring Poseida Therapeutics’ Advanced CAR-T Therapies Presented at American Society of Hematology 2017 Annual Meeting

SAN DIEGO, Dec. 11, 2017 — Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene engineering technologies into lifesaving cell therapies, today announced preclinical data from multiple chimeric antigen receptor T cell (CAR-T) programs in Poseida’s drug development pipeline.

“Our findings continue to demonstrate that our advanced gene engineering technologies, including our piggyBac™ DNA […]

By |December 11th, 2017|News|Comments Off on Multiple Programs Featuring Poseida Therapeutics’ Advanced CAR-T Therapies Presented at American Society of Hematology 2017 Annual Meeting

Poseida Therapeutics Presents Preclinical Solid Tumor Data for P-PSMA-101 at the American Association for Cancer Research Prostate Cancer Meeting

SAN DIEGO, Dec. 5, 2017 — Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene engineering technologies into lifesaving cell therapies, today presented preclinical data on P-PSMA-101, the company’s PSMA-specific chimeric antigen receptor T cell (CAR-T) stem cell memory drug candidate for the treatment of prostate cancer. P-PSMA-101 demonstrated potent anti-tumor efficacy, a […]

By |December 5th, 2017|News|Comments Off on Poseida Therapeutics Presents Preclinical Solid Tumor Data for P-PSMA-101 at the American Association for Cancer Research Prostate Cancer Meeting

Poseida Therapeutics Presents on the Development of Allogeneic and Autologous BCMA-Specific CAR-T Therapies at Precision: Blood Cancer Summit

SAN DIEGO, November 14, 2017 – Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene engineering technologies into lifesaving cell therapies, will participate today in a presentation on the development of its two anti-BCMA CAR-T programs: P-BCMA-101, the company’s BCMA-specific CAR-T drug candidate in a Phase 1 clinical trial for the treatment of […]

By |November 14th, 2017|News|Comments Off on Poseida Therapeutics Presents on the Development of Allogeneic and Autologous BCMA-Specific CAR-T Therapies at Precision: Blood Cancer Summit

Poseida Therapeutics to Present anti-PSMA CAR-T Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting

SAN DIEGO, November 8, 2017 – Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene therapy technologies into lifesaving cell therapies, today announced that preclinical data on P-PSMA-101, the company’s PSMA-specific chimeric antigen receptor T cell (CAR-T) stem cell memory drug candidate for the treatment of prostate cancer will be presented in a poster session at the Society for Immunotherapy of […]

By |November 8th, 2017|News|Comments Off on Poseida Therapeutics to Present anti-PSMA CAR-T Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting

Poseida Therapeutics’ CAR-T Programs to be Featured in Three Presentations at American Society of Hematology 2017 Annual Meeting

SAN DIEGO, November 2, 2017 – Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene therapy technologies into lifesaving cell therapies, today announced that three abstracts detailing preclinical data have been selected for presentation at the American Society of Hematology (ASH) Annual Meeting. Data will be presented at the 2017 ASH Annual Meeting in Atlanta on December 9th and 10th. Abstracts are currently available online at http://www.hematology.org/Annual-Meeting/Abstracts/.  

The following abstracts will be presented:
Presentation Title: The […]

By |November 2nd, 2017|News|Comments Off on Poseida Therapeutics’ CAR-T Programs to be Featured in Three Presentations at American Society of Hematology 2017 Annual Meeting

Poseida Awarded $19.8 Million CIRM Grant to Support Clinical Trial of P-BCMA-101, a T Stem Cell Memory CAR-T Therapy for Multiple Myeloma

SAN DIEGO, Oct. 26, 2017 — Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene therapy technologies into lifesaving cell therapies, today announced that the California Institute for Regenerative Medicine (CIRM) awarded a $19.8 million grant to support the clinical development of Poseida’s P-BCMA-101 product candidate. P-BCMA-101 is a chimeric antigen receptor T […]

By |October 26th, 2017|News|Comments Off on Poseida Awarded $19.8 Million CIRM Grant to Support Clinical Trial of P-BCMA-101, a T Stem Cell Memory CAR-T Therapy for Multiple Myeloma

Poseida Therapeutics Presents Preclinical Solid Tumor Data for P-PSMA-101, a CAR-T Therapy Predominantly Comprised of Stem Cell Memory T Cells, at the Prostate Cancer Foundation Annual Retreat

SAN DIEGO, October 5th, 2017 – Poseida Therapeutics Inc. (“Poseida”), a San Diego-based clinical-stage company translating best-in-class gene therapy technologies into lifesaving cell therapies, today presented preclinical data on P-PSMA-101, the company’s PSMA-specific chimeric antigen receptor T cell (CAR-T) stem cell memory drug candidate for the treatment of prostate cancer, showing potent anti-tumor activity, a […]

By |October 5th, 2017|News|Comments Off on Poseida Therapeutics Presents Preclinical Solid Tumor Data for P-PSMA-101, a CAR-T Therapy Predominantly Comprised of Stem Cell Memory T Cells, at the Prostate Cancer Foundation Annual Retreat